Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
ABC News18d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb. Dr. John Krystal of Yale University has led research on other schizophrenia drugs but was not involved in the new ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
BioSpace12h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
MedPage Today12d
Long-Term Data Support Efficacy, Safety of New Schizophrenia Drug
makes Cobenfy a highly welcomed addition for patients and providers." Approved in September, the drug was the first new class of drug for schizophrenia in over 30 years, with approval based on ...